Early and late stage MPN patients show distinct gene expression
profiles in CD34(+) cells

J 2021

Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells

BAUMEISTER, Julian, Tiago MAIE, Nicolas CHATAIN, Lin GAN, Barbora WEINBERGEROVÁ et. al.

Basic information

Original name

Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells

Authors

BAUMEISTER, Julian (276 Germany), Tiago MAIE (276 Germany), Nicolas CHATAIN (276 Germany), Lin GAN (276 Germany), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Marcelo A. S. DE TOLEDO, Joerg ESCHWEILER (276 Germany), Angela MAURER (276 Germany), Jiří MAYER (203 Czech Republic, belonging to the institution), Blanka KUBEŠOVÁ (203 Czech Republic, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic), Andreas SCHUPPERT (276 Germany), Ivan COSTA (276 Germany), Steffen KOSCHMIEDER (276 Germany), Tim H. BRUMMENDORF (276 Germany) and Deniz GEZER (276 Germany, guarantor)

Edition

Annals of Hematology, New York, Springer Verlag, 2021, 0939-5555

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.030

RIV identification code

RIV/00216224:14110/21:00122149

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1007/s00277-021-04615-8

UT WoS

000684908000001

Keywords in English

MPN; Gene expression; CD34

Abstract

V originále

Myeloproliferative neoplasms (MPN), comprising essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematological disorders of the myeloid lineage characterized by hyperproliferation of mature blood cells. The prediction of the clinical course and progression remains difficult and new therapeutic modalities are required. We conducted a CD34(+) gene expression study to identify signatures and potential biomarkers in the different MPN subtypes with the aim to improve treatment and prevent the transformation from the rather benign chronic state to a more malignant aggressive state. We report here on a systematic gene expression analysis (GEA) of CD34(+) peripheral blood or bone marrow cells derived from 30 patients with MPN including all subtypes (ET (n = 6), PV (n = 11), PMF (n = 9), secondary MF (SMF; post-ET-/post-PV-MF; n = 4)) and six healthy donors. GEA revealed a variety of differentially regulated genes in the different MPN subtypes vs. controls, with a higher number in PMF/SMF (200/272 genes) than in ET/PV (132/121). PROGEN. analysis revealed significant induction of TNF alpha/NF-kappa B signaling (particularly in SMF) and reduction of estrogen signaling (PMF and SMF). Consistently, inflammatory GO terms were enriched in PMF/SMF, whereas RNA splicing-associated biological processes were downregulated in PMF. Differentially regulated genes that might be utilized as diagnostic/prognostic markers were identified, such as AREG, CYBB, DNTT, TIMD4, VCAM1, and S100 family members (S100A4/8/9/10/12). Additionally, 98 genes (including CLEC1B, CMTM5, CXCL8, DACH1, and RADX) were deregulated solely in SMF and may be used to predict progression from early to late stage MPN.

Citovat

BAUMEISTER, Julian, Tiago MAIE, Nicolas CHATAIN, Lin GAN, Barbora WEINBERGEROVÁ, Marcelo A. S. DE TOLEDO, Joerg ESCHWEILER, Angela MAURER, Jiří MAYER, Blanka KUBEŠOVÁ, Zdeněk RÁČIL, Andreas SCHUPPERT, Ivan COSTA, Steffen KOSCHMIEDER, Tim H. BRUMMENDORF and Deniz GEZER. Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells. Annals of Hematology. New York: Springer Verlag, 2021, vol. 100, No 12, p. 2943-2956. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-021-04615-8.

@article{1787478,
   author = {Baumeister, Julian and Maie, Tiago and Chatain, Nicolas and Gan, Lin and Weinbergerová, Barbora and de Toledo, Marcelo A. S. and Eschweiler, Joerg and Maurer, Angela and Mayer, Jiří and Kubešová, Blanka and Ráčil, Zdeněk and Schuppert, Andreas and Costa, Ivan and Koschmieder, Steffen and Brummendorf, Tim H. and Gezer, Deniz},
   article_location = {New York},
   article_number = {12},
   doi = {http://dx.doi.org/10.1007/s00277-021-04615-8},
   keywords = {MPN; Gene expression; CD34},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of Hematology},
   title = {Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells},
   url = {https://link.springer.com/article/10.1007%2Fs00277-021-04615-8},
   volume = {100},
   year = {2021}
}

TY  - JOUR
ID  - 1787478
AU  - Baumeister, Julian - Maie, Tiago - Chatain, Nicolas - Gan, Lin - Weinbergerová, Barbora - de Toledo, Marcelo A. S. - Eschweiler, Joerg - Maurer, Angela - Mayer, Jiří - Kubešová, Blanka - Ráčil, Zdeněk - Schuppert, Andreas - Costa, Ivan - Koschmieder, Steffen - Brummendorf, Tim H. - Gezer, Deniz
PY  - 2021
TI  - Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells
JF  - Annals of Hematology
VL  - 100
IS  - 12
SP  - 2943-2956
EP  - 2943-2956
PB  - Springer Verlag
SN  - 09395555
KW  - MPN
KW  - Gene expression
KW  - CD34
UR  - https://link.springer.com/article/10.1007%2Fs00277-021-04615-8
N2  - Myeloproliferative neoplasms (MPN), comprising essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are hematological disorders of the myeloid lineage characterized by hyperproliferation of mature blood cells. The prediction of the clinical course and progression remains difficult and new therapeutic modalities are required. We conducted a CD34(+) gene expression study to identify signatures and potential biomarkers in the different MPN subtypes with the aim to improve treatment and prevent the transformation from the rather benign chronic state to a more malignant aggressive state. We report here on a systematic gene expression analysis (GEA) of CD34(+) peripheral blood or bone marrow cells derived from 30 patients with MPN including all subtypes (ET (n = 6), PV (n = 11), PMF (n = 9), secondary MF (SMF; post-ET-/post-PV-MF; n = 4)) and six healthy donors. GEA revealed a variety of differentially regulated genes in the different MPN subtypes vs. controls, with a higher number in PMF/SMF (200/272 genes) than in ET/PV (132/121). PROGEN. analysis revealed significant induction of TNF alpha/NF-kappa B signaling (particularly in SMF) and reduction of estrogen signaling (PMF and SMF). Consistently, inflammatory GO terms were enriched in PMF/SMF, whereas RNA splicing-associated biological processes were downregulated in PMF. Differentially regulated genes that might be utilized as diagnostic/prognostic markers were identified, such as AREG, CYBB, DNTT, TIMD4, VCAM1, and S100 family members (S100A4/8/9/10/12). Additionally, 98 genes (including CLEC1B, CMTM5, CXCL8, DACH1, and RADX) were deregulated solely in SMF and may be used to predict progression from early to late stage MPN.
ER  -

BAUMEISTER, Julian, Tiago MAIE, Nicolas CHATAIN, Lin GAN, Barbora WEINBERGEROVÁ, Marcelo A. S. DE TOLEDO, Joerg ESCHWEILER, Angela MAURER, Jiří MAYER, Blanka KUBEŠOVÁ, Zdeněk RÁČIL, Andreas SCHUPPERT, Ivan COSTA, Steffen KOSCHMIEDER, Tim H. BRUMMENDORF and Deniz GEZER. Early and late stage MPN patients show distinct gene expression profiles in CD34(+) cells. \textit{Annals of Hematology}. New York: Springer Verlag, 2021, vol.~100, No~12, p.~2943-2956. ISSN~0939-5555. Available from: https://dx.doi.org/10.1007/s00277-021-04615-8.

Detailed Information on Publication Record